Alnylam reported Q4 2025 adjusted EPS of $1.25, beating estimates, while revenue of $1.10 billion missed consensus despite 85% growth. Amvuttra sales surged 189% to $826.6 million. The stock fell 4.1% after the mixed results.
New research highlights strategies to overcome cancer drug resistance: a triple-drug AML combination, a breast cancer resistance target, evolutionary treatment switching, DNA damage mechanisms, and sildenafil's anti-metastatic potential.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Supreme Court unanimously reversed the Federal Circuit in Hikma v. Amarin, ruling that 'skinny label' generic marketing does not induce patent infringement absent active steps to encourage it. The decision requires affirmative conduct, not mere plausible interpretations, to support inducement claims.
A phase 3 trial shows that the oral drug enlicitide reduces LDL cholesterol by 60% compared to placebo, according to results published in the New England Journal of Medicine. Sponsored by Merck & Co., the trial involved 2,909 participants with atherosclerosis or at risk. If approved, enlicitide could help lower heart attack and stroke risk.
Updated pediatric hypertriglyceridemia guidance says triglyceride thresholds below 400 mg/dL mainly signal ASCVD risk, while levels above about 885 mg/dL raise pancreatitis risk. Lifestyle changes remain first-line treatment, and pediatric-specific evidence for drug therapy is still limited.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
A major meta-analysis of 19 randomized trials involving 123,940 participants found that only six side effects are actually caused by statins, challenging long-standing concerns about the drugs' safety profile.
A randomized trial found that men with prostate cancer treated with the GnRH agonist leuprolide experienced significantly more coronary artery plaque progression than those receiving the GnRH antagonist relugolix, suggesting a biological mechanism for cardiovascular risk differences between ADT drug pathways.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06134635 |
Short-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic Stroke |
NOT_YET_RECRUITING | |
| NCT03971019 |
Survival Benefits of Statins in Breast Cancer Patients |
UNKNOWN | PHASE3 |
| NCT03936361 |
Statins In Intracerbral Hemorrhage |
RECRUITING | PHASE3 |
| NCT03933293 |
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH |
COMPLETED | PHASE2 |
| NCT03770702 |
Statins and ARBs on Rheumatoid Activity |
RECRUITING | PHASE3 |
| NCT02890992 |
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia |
COMPLETED | PHASE2 |
| NCT02642159 |
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) |
COMPLETED | PHASE4 |
| NCT01972178 |
Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia |
TERMINATED | PHASE2 |
| NCT01738542 |
Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease |
COMPLETED | NA |
| NCT00968383 |
Cardiovascular Magnetic Resonance for the Occluded Infarct-Related Artery Treatment |
TERMINATED | NA |
